Sanofi India Ltd
NSE: SANOFI BSE: 500674
₹4040.70
(0.76%)
Wed, 25 Feb 2026, 04:08 pm
Market Cap92.73B
PE Ratio26.12
Dividend4.77
Health Technology
Pharmaceuticals: Major
24.5KCompany History
1956
- Incorporated as Hoechst Fedco Pharma Pvt. Ltd. on March 31.
- Established with financial and technical collaboration of Hoechst AG.
- Signed Licence and Technical Collaboration Agreement on July 11 granting HOECHST name and trademarks use.
- Issued 10,000 preference and 10,000 equity shares to promoters; 5,000 preference and 9,867 equity as rights.
1957
- Set up manufacturing unit at Mulund for basic drugs and intermediates.
1961
- Deleted 'Private' from name as deemed public limited company under Section 41-A.
- Issued 28,133 equity shares as rights.
1967
- Issued 37,800 bonus equity shares in 3:5 proportion.
- Issued 17,000 equity shares as rights.
1969
- Issued 57,222 bonus equity shares in 49:100 proportion.
1974
- Issued 164,990 bonus equity shares in 94:100 proportion.
1979
- Issued 170,256 bonus equity shares in 1:2 proportion.
1982
- Set up manufacturing unit at Kandla Free Trade Zone for exports.
- Issued 255,384 bonus equity shares in 1:2 proportion.
1984
- Issued 119,538 equity shares at Rs 100 premium; preferential allotment to associates and employees; balance to public.
1986
- Revalued land, buildings, plant, and machinery as of December 31.
- Incorporated subsidiary Hoechst Nepal Pvt. Ltd. in February.
1987
- Commissioned Haemaccel plant extension at Mulund and fine chemicals plant at Ankleshwar.
- Obtained industrial licence for Petoxifylline, Ciclopiroxolamine, diagnostic reagents.
1988
- Received industrial licence for RABIPUR rabies vaccine.
- Obtained MRTP Act approval for hybrid seeds undertaking.
- Issued 230,000 14% secured redeemable NCDs on private placement.
1989
- Re-entered antifungal market with BATRAFEN.
- Introduced insecticide HOSTATHION and poultry promoter FLAVOMYCIN.
- Commissioned pharma formulation plant at Ankleshwar and liquid injectables line at Mulund.
1990
- Introduced TARIVID, AVIL retard, TABLON, FLUROFEN.
- Received letters of intent and industrial licence for multiple products.
1991
- Introduced herbicide Klass, Butox, Tolzan.
- Received industrial licences and letters of intent for multiple products.
- Revalued freehold land and buildings; transferred surplus to reserves.
1992
- Introduced antihypertensive Rene Dil and anti-ulcer Rotane.
- Received industrial licences and letters of intent for multiple products.
- Commissioned additional super centrifuge for PCEC plant in Ankleshwar.
1993
- Issued 1,938,411 equity shares at Rs 60 premium to Hoechst AG, increasing stake to 51%.
1994
- Introduced Cardace, Typhoral oral typhoid vaccine, Candur-R antirabies vaccine.
- Transferred agrochemicals division to Hoechst Schering Agrfoo Ltd via scheme of arrangement.
- Issued 11,515,311 bonus equity shares in 1:1 proportion.
1995
- Launched INSUMAN human insulin and Floxidin antibiotic.
- Closed foot and mouth disease vaccine and Candur DHL plants.
- Amalgamated Roussel India Ltd; name changed to Hoechst Marion Roussel Ltd effective January 1, 1996.
1996
- Launched Insuman anti-diabetic drug.
- Suspended Baralgan production per government order.
- Expanded Rabipur plant capacity to 3.5 million doses per annum.
- Proposed joint venture with Chiron for vaccines.
1997
- Proposed introduction of Frisium, Amaryl, Cefrom, Targocil.
- Hoechst Roussel bought out stakes in Hoechst Roussel Vet Private Limited.
- Formed 50:50 JV Hoechst-Huabei Pharmaceuticals Co. Ltd.
1998
- Entered joint venture with Chiron Corporation in April for Rabipur manufacture and vaccine distribution rights.
- Purchased 33.33% stake in Roussel India from Roussel Laboratories UK.
- Planned transfer of animal healthcare business to JV with Chiron.
1999
- Launched voluntary retirement scheme at Mulund factory.
2000
- Planned introduction of Allegra and Tavanic variants.
- Ramesh Subrahmanian re-designated deputy managing director.
- Implemented employee stock option schemes.
- Acquired 2,955,608 equity shares of Rhone-Poulenc Rorer at Rs 15 per share.
- Hoechst Marion Roussel renamed Aventis Pharma.
2002
- Mr. W. Wagner appointed Director.
- Bombay High Court sanctioned amalgamation of Rhone-Poulenc Rorer with Aventis Pharma.
- Aventis Pharma sales increased 16% to Rs 261cr.
2003
- Aventis Pharma filed lawsuit alleging patent infringement.
- CRISIL withdrew AAA rating for Rs 30cr NCD issue.
- Mr. M.G. Rao and Dr. S. Bhattacharya appointed Alternate Directors.
- Ramesh Subramanian appointed VP Respiratory Sales for US regions.
2007
- Aventis Pharma appointed Mr. Eric Le-Bris as Additional Director.
- Aventis Pharma appointed Mr. S.C. Ghoge as Wholetime Director.
2008
- Aventis Pharma launched Lantus insulin in Solostar pen.
2010
- Mr. M. Dargentolle appointed Director.
- Mr. J. M. Georges and Mr. F. X. Duhalde appointed Additional Directors.
2011
- Aventis Pharma acquired nutraceutical business of Universal Medicare Private Limited.
- Sanofi India launched Fun Center for pediatric patients in Bangalore with HealthCare Global.
2012
- Sanofi India launched reusable insulin pen AllStar.
- Sanofi appointed Susheel Umesh as Head of Commercial Operations for Pharma in India.
- Company changed name from Aventis Pharma Ltd to Sanofi India Ltd.
2013
- Sanofi India launched Combiflam Plus.
- Sanofi tied up with IDF and PHFI against diabetes in children.
- Sanofi partnered with PVR Nest for Healthy Children initiative.
- Madhuri Dixit created diabetes dance step for Sanofi What Step Will You Take Today initiative.
- Sanofi inked pact with Suzlon Energy for renewable energy.
2014
- Sanofi partnered with Emcure for marketing and distribution of oncology portfolio in India.
2015
- Sanofi delivered 4 lakh Shan5 vaccine doses to Gwalior and Jabalpur.
- Sanofi India shifted registered office to Saki Vihar Road, Powai, Mumbai.
- Sanofi and RSSDI held Mega Walkathon for diabetes control in Lucknow.
2016
- Sanofi India collaborated with NIPER Kolkata for academic excellence and research.
2017
- Sanofi India launched Combiflam ICYHOT pain relief.
- 23 young people with type 1 diabetes scaled Maharashtra’s highest peak in first T1D Challenge.
2018
- Sanofi launched new diabetes treatment insulin in India.
- Sanofi launched multiple sclerosis treatment drug in India.
- Sanofi launched once-daily oral tablet Aubagio in India.
2019
- Sanofi India partnered to reduce diabetes burden on state's health exchequer.
2020
- Sanofi Pasteur launched VaxLine in India.
- Sanofi India launched Allergy Free.
- Sanofi Pasteur launched Tetraxim DTaP booster vaccine for preschoolers in India.
2021
- Sanofi India announced sale and transfer of Nutraceuticals business to Universal Nutriscience.
- Sanofi and GSK received approval for Phase 3 trial of COVID-19 vaccine candidate in India.
2023
- Sanofi received marketing approval for diabetes drug Soliqua in India.
2024
- Sanofi announced expansion of its Global Capability Centre in Hyderabad.
- Sanofi received marketing authorization for Beyfortus in India against RSV.
- Sanofi and Cipla announced exclusive distribution partnership for CNS portfolio in India.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800